开云网页登录_开云app官网入口下载苹果版

Abstract

CLC Number:

R593.23

References29

[1]	中华医学会风湿病学分会. 强直性脊柱炎诊断及治疗指南[J]. 中华风湿病学杂志, 2010, 14(8):557-559.
[2]	Magrey MN, Lewis S, Asim Khan M, et al. Utility of DXA scanning and risk factors for osteoporosis in ankylosing spondylitis-A prospective study[J]. Semin Arthritis Rheum, 2016, 46(1):88-94.
[3]	Ulu MA, Batmaz Ī, Dilek B, et al. Prevalence of osteoporosis and vertebral fractures and related factors in patients with ankylosing spondylitis[J]. Chin Med J, 2014, 127(15):2740-2747.
[4]	孔维萍, 张卫, 陶庆文, 等.1 051例强直性脊柱炎患者骨密度分析[J]. 中国骨质疏松杂志, 2012, 18(11):1036-1041.
[5]	Wang DM, Zeng QY, Chen SB, et al. Prevalence and risk factors of osteoporosis in patients with ankylosing spondylitis: a 5-year follow-up study of 504 cases[J]. Clin Exp Rheumatol, 2015, 33(4):465-470.
[6]	Malochet-Guinamand S, Pereira B, Tatar Z, et al. Prevalence and risk factors of low bone mineral density in spondyloarthritis and prevalence of vertebral fractures[J]. BMC Musculoskelet Disord, 2017, 18(1):357.
[7]	Maas F, Spoorenberg A, van der Slik BPG, et al. Clinical Risk Factors for the Presence and Development of Vertebral Fractures in Patients With Ankylosing Spondylitis[J]. Arthritis Care Res (Hoboken), 2017, 69(5):694-702.
[8]	Thomsen K, Jepsen DB, Matzen L, et al. Is calcaneal quantitative ultrasound useful as a prescreen stratification tool for osteoporosis?[J]. Osteoporos Int, 2015, 26(5):1459-1475.
[9]	孙红杰, 丛树国, 李旭光, 等. 超声检查对强直性脊柱炎患者骨质疏松的评估[J]. 中国继续医学教育, 2016, 8(30):54-55.
[10]	中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10(5):413-443.
[11]	Ulu MA, Çevik R, Dilek B, et al. Comparison of PA spine, lateral spine, and femoral BMD measurements to determine bone loss in ankylosing spondylitis[J]. Rheumatol Int, 2013, 33(7):1705-1711.
[12]	Klingberg E, Lorentzon M, Göthlin J, et al. Bone microarchitecture in ankylosing spondylitis and the association with bone mineral density, fractures, and syndesmophytes[J]. Arthritis Res Ther, 2013, 15(6):R179.
[13]	Sayed S, Darweesh H, Fathy K, et al. Clinical significance of bone mineral density in Ankylosing Spondylitis patients: Relation to disease activity and physical function[J]. Egyptian Rheumatologist, 2015, 37(1):35-39.
[14]	Vasdev V, Bhakuni D, Garg MK, et al. Bone mineral density in young males with ankylosing spondylitis[J]. Int J Rheum Dis, 2011, 14(1): 68-73.
[15]	Grazio S, Kusiéc Z, Cvijetiéc S, et al. Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectio-nal study[J]. Rheumatol Int, 2012, 32(9):2801-2808.
[16]	van der Weijden MA, van Denderen JC, Lems WF, et al. Low bone mineral density is related to male gender and decreased functional capacity in early spondylarthropathies[J]. Clin Rheumatol, 2011(4), 30(4):497-503.
[17]	Kisacik B, Tufan A, Kalyoncu U, et al. Mean platelet vo-lume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis[J]. Joint Bone Spine, 2008, 75(3):291-294.
[18]	Resorlu H, Resorlu M, Gokmen F, et al. Association between mean platelet volume and bone mineral density in patients with ankylosing spondylitis and diagnostic value of diffusion-weighted magnetic resonance imaging[J]. J Phys Ther Sci, 2015, 27(4):1137-1140.
[19]	Hinze AM, Louie GH. Osteoporosis Management in Ankylosing Spondylitis[J]. Curr Treat Options in Rheum, 2016, 2(4):271-282.
[20]	Zhang P, Li Q, Qi J, et al. Association between vitamin D receptor gene polymorphism and ankylosing spondylitis in Han Chinese[J]. Int J Rheum Dis, 2017, 20(10):1510-1516.
[21]	Cai G, Zhang X, Xin L, et al. Associations between vitamin D receptor gene polymorphisms and ankylosing spondylitis in Chinese Han population: a case-control study[J]. Osteoporos Int, 2016, 27(7):2327-2333.
[22]	谢建丽, 魏平, 王俊祥, 等. 维生素D在强直性脊柱炎骨代谢中的作用研究[J]. 中华风湿病学杂志, 2013, 17(11):771-774.
[23]	Khabbazi A, Noshad H, Gafarzadeh S, et al. Alendronate Effect on the Prevention of Bone loss in Early Stages of Ankylosing Spondylitis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study[J]. Iran Red Crescent Med J, 2014, 16(6):e18022.
[24]	Li G, Lv CA, Tian L, et al. A retrospective study of alendronate for the treatment of ankylosing spondylitis[J]. Medicine, 2018, 97(20): e10738
[25]	Kang K Y, Lee K Y, Kwok S K, et al. The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis[J]. Joint Bone Spine, 2011, 78(2):188-193.
[26]	Dubrovsky AM, Lim MJ, Lane NE, et al. Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton[J]. Calcif Tissue Int, 2018, 102(5):607-618.
[27]	Haroon NN, Sriganthan J, Al Ghanim N, et al. Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis[J]. Semin Arthritis Rheum, 2014, 44(2):155-161.
[28]	Li H, Li Q, Chen X, et al. Anti-tumor Necrosis Factor Therapy Increased Spine and Femoral Neck Bone Mi-neral Density of Patients with Active Ankylosing Spondylitis with Low Bone Mineral Density[J]. J Rheumatol, 2015, 42(8):1413-1417.
[29]	van der Weijden MA, van Denderen JC, Lems WF, et al. Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures: Results of a Prospective Observational Cohort Study[J]. J Rheumatol, 2016, 43(4):758-764.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References29

Related Articles2

Recommended Articles

Metrics

Comments

[1]	.[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 113-116.
[2]	.[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 341-343.